Fintechs that raked in profits from high interest rates now face a key test

Fintechs that raked in profits from high interest rates now face a key test


Key Points
  • In 2024, several fintechs — including Robinhood, Revolut and Monzo — saw a boost to their bottom lines from higher interest rates.
  • Now, they face a key test as a broad decline in interest rates raises doubts about the sustainability of relying on this heightened income over the long term.
  • Lindsey Naylor, partner at Bain & Company, said dropping benchmark rates could be “a test of the resilience of fintech firms’ business models.”



Source

Kevin Hassett pivots to possible ‘Trump cards’ amid credit card battle with banks
Finance

Kevin Hassett pivots to possible ‘Trump cards’ amid credit card battle with banks

Key Points Kevin Hassett told Fox Business that U.S. banks could voluntarily provide credit cards to underserved Americans. President Donald Trump called for banks to cap credit card interest rates at 10%, an idea that has been roundly rejected by industry executives and their lobbyists this week. At least one major credit card issuer and […]

Read More
Stocks making the biggest moves midday: Novo Nordisk, Vistra, GE Vernova, Regions Financial and more
Finance

Stocks making the biggest moves midday: Novo Nordisk, Vistra, GE Vernova, Regions Financial and more

Check out some of the companies making headlines in midday trading: Novo Nordisk — The maker of the Wegovy obesity treatment jumped more than 4% as sales of its oral weight loss treatment got off to a strong start. In the first week of its launch, about 1.3% of Wegovy prescriptions were for the oral […]

Read More
Stocks making the biggest moves premarket: PNC, ImmunityBio, Coupang & more
Finance

Stocks making the biggest moves premarket: PNC, ImmunityBio, Coupang & more

Check out the companies making headlines before the bell. ImmunityBio — The biotech company rallied 22%, adding to a 30% rally in the previous session that was sparked by strong guidance for its bladder cancer drug Anktiva. ImmunityBio expects full-year revenue for the drug to jump 700%. Coupang — Shares rose more than 3% after […]

Read More